Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphangiogenesis-dependent diseases

US10774131B2 · kind B2 · utility

Assignee

• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• Aleksander S. Popel · Timonium, US
• Elena V. Rosca · Baltimore, US
• Jacob E. Koskimaki · Baltimore, US
• Corban G. Rivera · Baltimore, US
• Niranjan B. Pandey · White Marsh, US
• Amir Tamiz · Silver Spring, US

Key dates

• Filing date: Sep 14, 2018
• Grant date: Sep 15, 2020
• Expiry date: Sep 14, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K7/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumori-genic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.